Prognostic value of serum β2-microglobulin in patients with waldenström's macroglobulinemia requiring treatment

Clinical Lymphoma and Myeloma

Volumn 7, Issue 3, 2006, Pages 205-209

  Anagnostopoulos, Athanasios ^a   Zervas, Konstantinos ^b   Kyrtsonis, Marie Christine ^a   Symeonidis, Argyris ^c   Gika, Dimitra ^a   Bourantas, Konstantinos ^d   Zomas, Athanasios ^e   Anagnostopoulos, Nikolaos ^e   Pangalis, Gerasimos ^a   Dimopoulos, Meletios Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

^e IASO GENERAL HOSPITAL   (Greece)

Author keywords

Anemia; B symptoms; Hyperviscosity; Lymphadenopathy; Splenomegaly

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BLOOD VISCOSITY; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; CYTOPENIA; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYPOALBUMINEMIA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SPLENOMEGALY; SURVIVAL TIME; THROMBOCYTOPENIA; WALDENSTROEM MACROGLOBULINEMIA;

EID: 37849188825     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.060     Document Type: Article

References (16)

1. Kyle RA, Greipp PR, Gertz MA, et al. Waidenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108:737-742.
2. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol 2003; 30:220-225.
3. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al. Waldenstrom's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol 2001; 80:722-727.
4. Dimopoulos MA, Hamilos G, Zervas K, et al. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol 2003; 14:1299-1305.
5. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553-1558.
6. Dimopoulos MA, Alexanian R. Waldenstrom's macroglobulinemia. Blood 1994; 83:1452-1459.
7. Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 1994; 83:2939-2945.
8. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852-858.
9. Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115:575-582.
10. Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:211-215.
11. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:110-115.
12. Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:127-131.
13. Dimopoulos MA, Kyrtsonis MC, Tsatalas C, et al. Primary treatment of Waldenstrom's macroglobulinemia with dexamethasone, rituximab and cyclophosphamide. Blood 2004; 104:215a (Abstract #752).
14. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98:41-48.
15. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23:1564-1577.
16. Treon SP, Gertz MA, Dimopoulos M et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia. Blood 2006 (Epub ahead of print).